An extension study to evaluate the long-term efficacy and safety of minzasolmin (UCB0599) in study participants with Parkinsons disease

Brief description of study

Subjects currently enrolled in the PD0053 can be enrolled in this study. Subjects will take UCB0599 capsules twice a day at either 180 mg or 360 mg approximately 12 hours apart. The start of the study will overlap with the end of the parent study and run for 30 months with a one month safety follow up at the conclusion of treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

TBD

Updated on 10 Apr 2024. Study ID: 855493

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).